Please login to the form below

Not currently logged in

Penn Pharma begins £12m expansion

Penn Pharma has completed the first phase of its £12m expansion programme by investing £315k in extending its facilities

Partly backed by the Welsh Assembly Government's Single Investment Fund, Penn Pharma has completed the first phase of its £12m expansion programme by investing £315k in extending its facilities by 2400m2 and changing the transport and delivery infrastructure at its Tredegar headquarters. 

Peter George, CEO of Penn Pharma, said: "By heavily investing in our Tredegar site it strengthens our commitment to the local community and, as a leading Welsh company, we will endeavour to pay back the Assembly Government's faith in us by driving sustainable growth and employment."

Penn, founded 30 years ago, is a highly specialised pharmaceutical company which combines an integrated pharmaceutical development service with low volume clinical and commercial manufacturing. Its services support a fast and effective route from clinic to market. The company has achieved very strong growth in recent years, with customers from many of the world's leading pharmaceutical companies in the UK, EU and USA.
The company plans to roll out its £12m expansion plans over the next five years.

2nd November 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...